Blue Trust Inc’s Axsome Therapeutics AXSM Stock Holding History

Blue Trust Inc’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$738	Hold	4	–	–	﹤0.01%	2222
2026 Q2	$979	Hold	4	–	–	﹤0.01%	2301
2026 Q1	$676	Hold	4	–	–	﹤0.01%	2309
2025 Q4	$731	Buy	+4	New	+$558	﹤0.01%	2338
2025 Q2	–	Sell	-113	Closed	-$13.2K	–	2459
2025 Q1	$13.2K	Hold	113	–	–	﹤0.01%	1789
2024 Q4	$9.6K	Buy	113 +38	+51%	+$3.49K	﹤0.01%	1945
2024 Q3	$6.04K	Buy	75 +27	+56%	+$2.36K	﹤0.01%	2348
2024 Q2	$3.83K	Buy	+48	New	+$3.55K	﹤0.01%	2277
2024 Q1	–	Sell	-38	Closed	-$3K	–	2199
2023 Q4	$3K	Buy	+38	New	+$2.54K	﹤0.01%	1982

Other funds holding AXSM

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return

Iridian Asset Management Westport, Connecticut $275M AUM 37.66% 1-Year Est. Return

Baldwin Wealth Partners Marion, Massachusetts $1.52B AUM 21.45% 1-Year Est. Return

Washington Trust Advisors Wellesley, Massachusetts $1.4B AUM 26.88% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Stanley-Laman Group Berwyn, Pennsylvania $915M AUM 50.26% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Blue Trust Inc's AXSM Position: Q3 2026 in Review

Blue Trust Inc held its Axsome Therapeutics (AXSM) position steady in Q3 2026 at 4 shares worth $738. The position accounts for ﹤0.01% of the portfolio, ranked #2222.

Blue Trust Inc first reported a position in AXSM in Q4 2023 and has held it in 9 quarters since. The position peaked at $13.2K in Q1 2025. 63 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

Blue Trust Inc held 4 shares of Axsome Therapeutics worth $738 as of Q3 2026.
Blue Trust Inc left its Axsome Therapeutics share count unchanged in Q3 2026.
Axsome Therapeutics made up ﹤0.01% of Blue Trust Inc's portfolio in Q3 2026, its #2222 holding.
Blue Trust Inc first reported a position in Axsome Therapeutics in Q4 2023 and has held it in 9 quarters since.
Blue Trust Inc's Axsome Therapeutics position peaked at $13.2K in Q1 2025.
63 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Blue Trust Inc's 13F filing for Q3 2026, filed 15 Oct 2026.